# Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

Article · Barbara M. McGowan, Jens Meldgaard Bruun, Matt Capehorn, Sue D. Pedersen, Kirsi Hannele Pietiläinen, Hanna Angelene, Maria Quiroga, Anette Varbo, David C.W. Lau

- Archive id: doi:10.1016/s2213-8587(24)00182-7
- Published: 2024-07-29
- Venue: The Lancet Diabetes & Endocrinology
- DOI: https://doi.org/10.1016/s2213-8587(24)00182-7
- PMID: 39089293
- Citations: 175
- Source URL: https://doi.org/10.1016/s2213-8587(24)00182-7
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.